AGAMREE Drug Patent Gets FDA Review Period Seal
Published Date: 6/25/2025
Notice
Summary
The FDA has officially set the review period for AGAMREE, a human drug product, so its patent can be extended. This helps the company get extra time to protect their invention after the long approval process. If you’re involved in drug patents or development, this timing update could impact your plans and profits.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Regulatory Review Period Set for AGAMREE
The FDA has determined the regulatory review period for AGAMREE, a human drug product, and published a notice so a patent on that drug can be extended. The Agency made this determination because applications were submitted to the U.S. Patent and Trademark Office asking for a patent extension. If you work on drug patents or drug development, this timing update is directly relevant to planning patent-extension actions.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in